Sareum Holdings plc (AIM:SAR)

London flag London · Delayed Price · Currency is GBP · Price in GBX
11.50
-0.75 (-6.12%)
Mar 25, 2025, 12:25 PM GMT+1
-30.30%
Market Cap 14.05M
Revenue (ttm) n/a
Net Income (ttm) -2.83M
Shares Out 124.93M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 294,122
Average Volume 814,990
Open 12.01
Previous Close 12.25
Day's Range 11.50 - 12.01
52-Week Range 10.00 - 52.50
Beta -1.25
RSI 15.94
Earnings Date Mar 21, 2025

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange London Stock Exchange AIM
Ticker Symbol SAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.